Home > Search Results

About - Ependymoma

A type of brain tumor that begins in cells lining the spinal cord central canal (fluid-filled space down the center) or the ventricles (fluid-filled spaces of the brain).

Results: 16

Childhood Ependymoma Treatment (PDQ®): Patient Version

Expert-reviewed information summary about the treatment of childhood ependymoma.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: April 7, 2017

Childhood Ependymoma Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of childhood ependymoma.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: April 6, 2017

Immunohistochemical prognostic markers in intracranial ependymomas: systematic review and meta-analysis

Distinction between grade II ependymomas and anaplastic ependymomas based on histopathological examination solely is problematic and, therefore, the management of intracranial ependymomas remains controversial. The aim of this study was to conduct a systematic review (SR) and meta-analysis (MA) of data published on immunohistochemical prognostic markers (IPM) in intracranial ependymomas (IE), and to establish an evidence-based perspective on their clinical value. Following the extensive search based on a strictly defined group of key words, 30 studies reporting results on IPM in IE were identified. Due to a pronounced inter-study heterogeneity, only 14 publications fulfilled the criteria for inclusion into SR. From the total of 67 immunohistochemical markers, 18 were found to correlate with prognosis. However, owing to inadequate data publishing, MA could be performed only with data on proliferation marker MIB-1 (Ki-67) from 5 publications, including 337 patients: The pooled hazard ratio for overall survival was 3.16 (95% confidence interval = 1.96-5.09; p < 0.001) implicating that patients suffering from tumors with higher immunohistochemical expression of MIB-1 had a significantly worse outcome. Marked inter-study heterogeneity and incomplete data publishing in primary studies significantly limited extent of the SR, and the possibility of performing MA. Although the prognostic impact of MIB-1 immunoexpression in IE could be confirmed, there remains lack of further reliable IPM that could be used in routine diagnosis. We encourage to search for new, useful markers, as well as to standardize lab-techniques and data interpretation algorithms across laboratories in order to increase data compatibility.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Entyvio (Vedolizumab) [Internet]

The objective of this report is to perform a systematic review of the beneficial and harmful effects of vedolizumab intravenous (IV) infusion in accordance with the Health Canada–approved indication for the treatment of Crohn’s disease. Vedolizumab has been previously reviewed through the CADTH Common Drug Review (CDR) for the treatment of ulcerative colitis.

Common Drug Review - Canadian Agency for Drugs and Technologies in Health.

Version: December 2016
Show search results within this document

Childhood Brain and Spinal Cord Tumors Treatment Overview (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of various childhood brain tumors.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: February 8, 2017

Adult Central Nervous System Tumors Treatment (PDQ®): Patient Version

Expert-reviewed information summary about the treatment of adult central nervous system tumors.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: August 26, 2016

Childhood Brain and Spinal Cord Tumors Treatment Overview (PDQ®): Patient Version

Expert-reviewed information summary about the treatment of various childhood brain tumors.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: February 8, 2017

Adult Central Nervous System Tumors Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of adult central nervous system tumors.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: January 31, 2017

Genetics of Endocrine and Neuroendocrine Neoplasias (PDQ®): Health Professional Version

Expert-reviewed information summary about the genetics of endocrine and neuroendocrine neoplasias. This summary contains information about the MEN1 gene, the RET gene, genetic testing, and clinical interventions. Psychosocial issues associated with genetic testing and counseling of individuals who may have a hereditary medullary thyroid cancer syndrome are also discussed.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: April 14, 2017

Childhood Cancer Genomics (PDQ®): Health Professional Version

Expert-reviewed information summary about the genomics of childhood cancer. The summary describes the molecular subtypes for specific pediatric cancers and their associated clinical characteristics, the recurring genomic alterations that characterize each subtype at diagnosis or relapse, and the therapeutic and prognostic significance of the genomic alterations. The genomic alterations associated with brain tumors, kidney tumors, leukemias, lymphomas, sarcomas, and other cancers are discussed.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: February 3, 2017

Ovarian Germ Cell Tumors Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of ovarian germ cell tumors.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: February 12, 2016

Proton Beam Therapy versus Photon Radiotherapy for Adult and Pediatric Oncology Patients: A Review of the Clinical and Cost-Effectiveness [Internet]

There is much interest in increasing the availability of photon therapy — proton beam therapy (PBT) in Canada, but increased costs, implementation concerns, and unsubstantiated comparative clinical benefit and harms compared to other cancer radiotherapy treatments should be considered. This review will evaluate evidence on the comparative clinical and cost-effectiveness of PBT and photon radiotherapy in adult and pediatric patients requiring radiotherapy for the treatment of cancer.

Rapid Response Report: Summary with Critical Appraisal - Canadian Agency for Drugs and Technologies in Health.

Version: May 20, 2016
Show search results within this document

Newcastle Disease Virus (PDQ®): Health Professional Version

Expert-reviewed information summary about the use of Newcastle disease virus (NDV) as a treatment for people with cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: November 2, 2016

Melanoma: Assessment and Management

Cutaneous melanoma is increasing in incidence in many of the developed countries as this form of cancer occurs predominantly in pale skinned people who expose themselves to intense sunlight, especially when taking holidays in sunny places. The increased work-load for melanoma services resulting from this increase is furthermore complicated by the fact that the individuals with the most rapid rate of increase in incidence are those over the age of 60 and especially men. Male sex and age are two poor prognostic factors for melanoma and therefore the likelihood is that despite efforts to promote primary and secondary melanoma prevention, melanoma mortality is likely to increase rather than decrease. Although the incidence trends described above are of concern, for the first time in very recent years, the advent of therapies targeted to driver mutations (such as inhibitors of BRAF) and of T cell checkpoint inhibitors which both have efficacy in melanoma is in the process of rapidly changing management of this disease. Use of both classes of drugs has been the subject of NICE technology appraisals in recent years and these have been cross referenced in the text.

NICE Guideline - National Collaborating Centre for Cancer (UK).

Version: July 2015
Show search results within this document

Suspected Cancer: Recognition and Referral

Cancer is an important condition, both in terms of the number of people affected and the impacts on those people and the people close to them. Around one third of a million new cancers are diagnosed annually in the UK, across over 200 different cancer types. Each of these cancer types has different presenting features, though there may be overlap. More than one third of the population will develop a cancer in their lifetime. Although there have been large advances in treatment and survival, with a half of cancer sufferers now living at least ten years after diagnosis, it remains the case that more than a quarter of all people alive now will die of cancer.

NICE Guideline - National Collaborating Centre for Cancer (UK).

Version: June 2015
Show search results within this document

Transient Loss of Consciousness (‘Blackouts’) Management in Adults and Young People [Internet]

There are a number of existing guidelines, for epilepsy, falls and cardiac arrhythmias; which all relate to transient loss of consciousness (TLoC), but there is no guideline which addresses the initial assessment and management of patients who blackout. As such patients may come under the care of a range of clinicians, the lack of a clear pathway contributes to their misdiagnosis, and inappropriate treatment.

NICE Clinical Guidelines - National Clinical Guideline Centre for Acute and Chronic Conditions (UK).

Version: August 2010
Show search results within this document

Systematic Reviews in PubMed

See all (58)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...